By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Tisotumab vedotin-tftv (monograph) > Tisotumab Vedotin Dosage
Drugs
https://themeditary.com/dosage-information/tisotumab-vedotin-dosage-10593.html

Tisotumab Vedotin Dosage

Drug Detail:Tisotumab vedotin-tftv (monograph) (Tivdak)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Cervical Cancer

2 mg/kg (up to a maximum of 200 mg for patients 100 kg or greater) IV over 30 minutes every 3 weeks until disease progression or unacceptable toxicity

Premedication and Eye Care:

  • Conduct an ophthalmic exam including visual acuity and slit lamp exam at baseline, prior to each dose, and as indicated.
  • The initial prescription and all renewals of any corticosteroid medications should be made only after examination with a slit lamp.
  • Administer the first drop in each eye prior to each infusion; continue to administer the drops in each eye 72 hours after each infusion.
  • Administer topical ocular vasoconstrictor drops in each eye immediately prior to each infusion.
  • Use cooling eye pads during the infusion.
  • Administer topical lubricating eye drops for the duration of therapy and for 30 days after the last dose.
  • Advise patients to avoid wearing contact lenses unless advised by their eye care provider for the entire duration of therapy.

Use: For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild hepatic impairment: No adjustment recommended.
Moderate or severe hepatic impairment: Not recommended.

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:

  • Starting dose: 2 mg/kg
  • First dose reduction: 1.3 mg/kg
  • Second dose reduction: 0.9 mg/kg
NOTE: Permanently discontinue therapy in patients who cannot tolerate 0.9 mg/kg

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
KERATITIS:
Superficial Punctate Keratitis (SPK):
  • Any: Monitor
Confluent Superficial Keratitis (CSK):
  • First occurrence: Withhold dose until SPK or normal, then resume therapy at the next lower dose level
  • Second occurrence: Permanently discontinue therapy
Ulcerative keratitis or perforation:
  • Any: Permanently discontinue therapy
CONJUNCTIVAL ULCERATION:
Any Ulceration:
  • First occurrence: Withhold dose until complete conjunctival re-epithelialization, then resume therapy at the next lower dose level
  • Second occurrence: Permanently discontinue therapy
CONJUNCTIVAL OR CORNEAL SCARRING OR SYMBLEPHARON:
Any Scarring or Symblepharon:
  • Any: Permanently discontinue therapy
CONJUNCTIVITIS AND OTHER OCULAR ADVERSE REACTIONS:
Grade 1:
  • Any: Monitor
Grade 2:
  • First occurrence: Withhold dose until Grade 1 or less then resume at the same dose
  • Second occurrence: Withhold dose until Grade 1 or less then resume at the next lower dose level; if no resolution to Grade 1 or less, permanently discontinue therapy
  • Third occurrence: Permanently discontinue therapy
Grade 3 or 4:
  • Any: Permanently discontinue therapy
Grade 3 or 4:
  • Any: Permanently discontinue therapy
PERIPHERAL NEUROPATHY:
Grade 2:
  • Any (initial or worsening of pre-existing condition): Withhold dose until Grade 1 or less, then resume at the next lower dose
Grade 3 or 4:
  • Any: Permanently discontinue therapy
HEMORRHAGE:
Any Grade Pulmonary or Central Nervous System (CNS):
  • Any: Permanently discontinue therapy
Grade 2 in Any Other Location:
  • Any: Withhold therapy until resolved then resume at the same dose
Grade 3 in Any Other Location:
  • First occurrence: Withhold dose until resolved then resume at the same dose
  • Second occurrence: Permanently discontinue therapy
Grade 4 in Any Other Location:
  • Any: Permanently discontinue therapy
PNEUMONITIS:
Grade 2:
  • Any: Withhold dose until Grade 1 or less for persistent or recurrent pneumonitis; consider resuming therapy at next lower dose level
Grade 3 or 4:
  • Any: Permanently discontinue therapy

Precautions

US BOXED WARNINGS:
OCULAR TOXICITY:

  • This drug causes changes in the corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration.
Recommendations:
  • Perform an ophthalmic exam at baseline, prior to each dose, and as indicated.
  • Adhere to premedication and required eye care before, during, and after infusion.
  • Withhold therapy until improvement and resume, reduce the dose, or permanently discontinue, based on severity.

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug is available for IV administration; do not administer as IV push or bolus.

Storage requirements:
  • Store vial refrigerated at 2C to 8C (36F to 46F) in the original carton to protect from light; do not freeze; do not shake.

Reconstitution/preparation techniques:
  • Use aseptic technique for reconstitution and preparation of this drug.
  • The manufacturer product information should be consulted.

IV compatibility:
  • Dextrose 5% Injection
  • Sodium Chloride 0.9% Injection
  • Lactated Ringer's Injection

Monitoring:
  • Renal
  • Hepatic

Patient advice:
  • This drug can harm a developing baby.
  • Proper ocular care is essential when receiving this drug.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by